antidepressant news from FiercePharma
NewsWyeth discounts Pristiq for big sales push
Think the latest-and-greatest drug would naturally be the most expensive? Think again. Now that its Pristiq antidepressant is Read more...
Could full data disclosure avert scandal?
New calls for old drug data in the U.K. have experts second-guessing big drug-safety scandals. If scientists and regulators had had access to every bit of data on Vioxx from the get-go, for instance, Read more...
Brits pledge law change after GSK probe
GlaxoSmithKline is off the hook in a U.K. investigation of its withholding data on the antidepressant Seroxat, sold as Paxil in the U.S. The four-year probe sought to determine whether Glaxo acted Read more...
SPOTLIGHT: FDA OKs Wyeth's antidepressant Pristiq
Wyeth announced late Friday that it won FDA approval for Pristiq, its next-generation version of the antidepressant Effexor. Wyeth was looking for an approval of Pristiq to offset the Read more...
Drug makers jack prices up 7.8%
Maybe drug makers shouldn't be surprised when presidential candidates hammered them for high prices. Last year, drugmakers continued to raise the costs of prescription drugs, according to a market Read more...
The specter of generic competition grows
We can officially call 2007 the year generic competition became a byword on the markets as well as in Big Pharma hallways. It's always first on the list of ills plaguing the industry (followed by Read more...
Lilly cited for"misleading" Cymbalta ads
While Eli Lilly's CEO was out lobbying for drug safety, the FDA was posting a letter on its website warning the drug maker to stop making "false and misleading" claims about its antidepressant Read more...
BMS to pay $515M in kickback case
Bristol-Myers Squibb now has the dubious distinction of the third-largest court settlement between a drug maker and the U.S. Attorney's office in Massachusetts. The drug maker agreed to pay $515 Read more...
Suicide stats fuel debate over SSRI drugs
The unintended consequences of managing SSRI drugs can be severe, according to a new federally-funded study of suicidal behavior among children. In 2003, the feds warned that the widely used Read more...
Forest Labs gets Lexapro protection
How does Forest Labs spell relief? P-A-T-E-N-T. A federal court has validated the company's Lexapro protection, safeguarding that blockbuster antidepressant and antianxiety drug through 2012. The Read more...
| Press ReleasesPRESS RELEASE: A faster class of antidepressants A faster class of antidepressants Studies with rats have revealed the potential in an entirely new class of antidepressants that take effect after only days of treatment versus the weeks required Read more... |
Get more antidepressant coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets